The risk of specific breast cancer subtypes may not be associated with BMI in pre- and postmenopausal breast cancer. However, obesity might be related to an increased risk of premenopausal hormone receptor-negative breast cancer. Further studies are needed for clarification of the probable mechanisms in the pathogenesis of premenopausal hormone receptor-negative breast cancer.
A ntineoplastic agents have been shown to cause easily identifiable pigmentary changes involving the skin, mucosa, and appendages in literature. Supravenous hyperpigmentation is a rare complication of chemotherapy administration, easily differentiated from other forms of pigmentations, by its characteristic appearance following the course of the vessels, the antineoplastic agent is administered to. Here, we describe a case of supravenous hyperpigmentation induced by the vinca alkaloid, vinorelbine.The patient is a 51-year-old female, who presented in with a mass in the right breast. A biopsy was performed in May 2005 which revealed estrogen receptor positive (ER+), progesteron receptor positive (PR+), Cerb-B2 1+ infiltrative carcinoma. A thoracic spinal magnetic resonance imaging was conducted, which revealed metastasis in T10, L1, and L5. A thoracic computer tomography (CT) was taken which revealed a mass in the upper right quadrant of the right breast, laterally smaller dispersed nodules and right axillary lymphadenopathy. In September 2007, a bone scintigraphy was performed which demonstrated findings consistent with disseminated bone metastasis. Also, an upper and lower abdominal CT was performed which revealed masses in the liver and bones, originating from the malignancy. Afterward a right mastectomy was performed; the specimen was grade 2 ER, PR+ cerb 2 1+ mixed infiltrative carcinoma. Following chemotherapy, follow-up thoracic, and abdominal CT imaging was performed to evaluate the progress, which showed that the disseminated sclerotic bone metastasis had not regressed whereas the liver metastasis had lessened in size. In the thorax CT performed in July 2011, lung metastasis was also identified. 160 mg of megestrol acetate, twice daily was recommended. Last, the patient was prescribed six cycles of vinorelbine.During the first half hour of the administration of vinorelbine, the patient developed hyperpigmented lesions in the left anterior part of the forearm. With each administration of vinorelbine, the pigmentation got darker in color. (Fig. 1) A biopsy was requested but denied. Following a detailed physical examination, a literature review was performed to identify other cases with similar characteristics. The patient was diagnosed with persistent serpentine supravenous hyperpigmentation due to the administration of vinorelbine; and was asked to return for follow-up after her regimen was completed. During follow-up, in time, the hyperpigmented areas around the course of the veins, with which the chemotherapeutic agent was administered, faded, as also observed by other cases present in literature.
e11509 Background: Distant spread from breast cancer is commonly found in bones, lungs, liver, and central nervous system. However, peritoneal involvement is unusual and unexpected. The aim of the study was to perform a comprehensive analysis of breast cancer patients with peritoneal metastases. Methods: Twenty-one (0.9% of the cohort) breast cancer patients with peritoneal metastases were detected out of a database of 2,219 breast cancer patients treated in Hacettepe University Medical Oncology Department. Clinical characteristics, follow up times and survival rates were analyzed. Results: The mean age of the 21 patients at the time of peritoneal metastasis was 56 years (38-71). 12 (57.1%) patients were post-menopausal, 6 (28.6%) patients were pre-menopausal. Numbers of deceased patients were 7 (33.3%). Seven (33.3%) patients’ histological subtypes were invasive ductal carcinoma (IDC), five (23.8%) patients’ were invasive lobular carcinoma (ILC) and three (14.3%) patients’ were mixed (IDC and ILC). Numbers of luminal A patients were 8 (38.1%), luminal B were 5 (23.8%), triple negative were 2 (9.5%). There was no Her-2 overexpressing patient and numbers of unknown molecular subtype patients were 6 (28.6%). The median follow up times after peritoneal disease in patients deceased and living were 9.3 (range: 0.4-23.3) months and 15.6 (range: 0.3-40.4) months, respectively. Median follow up time after peritoneal metastasis of ER positive patients was 13.7 months, and it was longer than ER negative patients (4.4 months). Six months and one year survival rates after peritoneal metastasis were 83.3% and 73.3%, respectively. Disease free, progression free and overall survival data could not be obtained due to inadequate number of events. Conclusions: Peritoneal metastasis of breast cancer is very rare and median survival time is controversial in literature. Despite of a small cohort, we found the patients’ follow up times longer than reported before. Especially, ER positive patients have longer survival time than ER negative, and this result highlights the importance of hormonotherapies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.